IL-17 Inhibitor Therapy and Risk of Chronic Obstructive Pulmonary Disease and Related Pulmonary Outcomes in Patients with Psoriasis: A Real-World Cohort Study.

Taltz (ixekizumab) - Eli Lilly

Bimzelx (bimekizumab-bkzx) - UCB

Cosentyx (secukinumab) - Novartis

Siliq (brodalumab) - Bausch Health

http://www.ncbi.nlm.nih.gov/pubmed/42314776

Jessica Lori Feig; Kushal Kriplani; Michael Kozlov; Mohammad Al-Ajam; Robert Adler; Sabrina Muhanna

Jun 19, 2026